Vertex Pharmaceuticals Incorporated (VRTX) Just Jumped & Could Jump Again

Sales on track

Kalydeco has already earned the company up to about $171.6 million. The fact that it only targets 4% of the Cystic Fibrosis population is good in itself. Let us also not forget the fact that Kalydeco is expected to make sales of $1 billion or more. If this experimental Cystic Fibrosis trial gets approved by the FDA, then profit is expected to be higher. Analysts are expecting $4 billion or more in annual revenue once it’s approved.

Final thought

Vertex had popped up big on its new Cystic Fibrosis data, and has started to drift in the $80 per share range. Granted, the share price will swing in a certain range for now, I expect further data on the Cystic Fibrosis drug to boost the stock once again. The company faces tough challenges ahead on its Incivek drug against competing Hepatitis C drugs. Despite this, with no other competitor in the Cystic Fibrosis Space, I would say that Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a strong long-term buy.

The article This Biotech Just Popped, and Might Pop Further originally appeared on Fool.com.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.